Diabetes Prevention: Can Insulin Secretagogues Do the Job?

Overview

Journal Prim Care Diabetes

Publisher Elsevier

Specialties Endocrinology
Public Health

Date 2010 Dec 28

PMID 21185798

Citations 3

Authors

Barbara Westerhaus

Aidar R Gosmanov

Guillermo E Umpierrez

Affiliations

Soon will be listed here.

Abstract

The recent Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial reported that nateglinide, a non-sulfonylurea insulin secretagogue, failed to prevent progression from impaired glucose tolerance to diabetes. In order to determine the beneficial effect of insulin secretagogues as a class in diabetes prevention, we performed a literature search for randomized controlled studies and review articles on diabetes prevention and use of sulfonylureas, nateglinide, and meglitinide in PubMed and Ovid Medline since 1950. Three studies were identified with none of them reporting success in preventing diabetes, indicating that insulin secretagogues should not be recommended for diabetes prevention.

Citing Articles

A Microtube-Based Wearable Closed-Loop Minisystem for Diabetes Management.

Liu Y, Yu Q, Luo X, Ye L, Yang L, Cui Y Research (Wash D C). 2022; 2022:9870637.

PMID: 36349339 PMC: 9639446. DOI: 10.34133/2022/9870637.

Anti-Diabetic Effect of Portulaca oleracea L. Polysaccharideandits Mechanism in Diabetic Rats.

Bai Y, Zang X, Ma J, Xu G Int J Mol Sci. 2016; 17(8).

PMID: 27463713 PMC: 5000599. DOI: 10.3390/ijms17081201.

Beta Cell Function and the Nutritional State: Dietary Factors that Influence Insulin Secretion.

Moore W, Bowser S, Fausnacht D, Staley L, Suh K, Liu D Curr Diab Rep. 2015; 15(10):76.

PMID: 26294335 DOI: 10.1007/s11892-015-0650-1.

References

Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle T, Hamalainen H . Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J Clin Endocrinol Metab. 2004; 89(12):6286-90. DOI: 10.1210/jc.2004-1204. View

Leahy J, Hirsch I, Peterson K, Schneider D . Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010; 95(9):4206-16. DOI: 10.1210/jc.2010-0668. View

Ratzmann K, Witt S, Schulz B . The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance. Diabete Metab. 1983; 9(2):87-93. View

Abdul-Ghani M, Tripathy D, DeFronzo R . Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006; 29(5):1130-9. DOI: 10.2337/diacare.2951130. View

Saloranta C, Guitard C, Pecher E, de Pablos-Velasco P, Lahti K, Brunel P . Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care. 2002; 25(12):2141-6. DOI: 10.2337/diacare.25.12.2141. View

Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T . Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008; 359(21):2220-32. DOI: 10.1056/NEJMoa0801869. View

Zinman B, Harris S, Neuman J, Gerstein H, Retnakaran R, Raboud J . Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010; 376(9735):103-11. DOI: 10.1016/S0140-6736(10)60746-5. View

Chanoine J, Hampl S, Jensen C, Boldrin M, Hauptman J . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005; 293(23):2873-83. DOI: 10.1001/jama.293.23.2873. View

DeFronzo R . Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4):773-95. PMC: 2661582. DOI: 10.2337/db09-9028. View

10.

Huang E, Basu A, OGrady M, Capretta J . Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009; 32(12):2225-9. PMC: 2782981. DOI: 10.2337/dc09-0459. View

11.

Abdul-Ghani M, DeFronzo R . Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care. 2009; 32 Suppl 2:S194-8. PMC: 2811468. DOI: 10.2337/dc09-S309. View

12.

Weyer C, Bogardus C, Pratley R . Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 1999; 48(11):2197-203. DOI: 10.2337/diabetes.48.11.2197. View

13.

Gouda H, Sagoo G, Harding A, Yates J, Sandhu M, Higgins J . The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol. 2010; 171(6):645-55. PMC: 2834889. DOI: 10.1093/aje/kwp450. View

14.

Touyz R, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R . The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. Can J Cardiol. 2004; 20(1):55-9. View

15.

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

16.

Florez J, Jablonski K, Sun M, Bayley N, Kahn S, Shamoon H . Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007; 92(4):1502-9. PMC: 2267936. DOI: 10.1210/jc.2006-2275. View

17.

Karunakaran S, Hammersley M, Morris R, Turner R, Holman R . The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism. 1998; 46(12 Suppl 1):56-60. DOI: 10.1016/s0026-0495(97)90319-x. View

18.

Gerstein H, Santaguida P, Raina P, Morrison K, Balion C, Hunt D . Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007; 78(3):305-12. DOI: 10.1016/j.diabres.2007.05.004. View

19.

DeFronzo R, Tripathy D . Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009; 32 Suppl 2:S157-63. PMC: 2811436. DOI: 10.2337/dc09-S302. View

20.

Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjogren M, Saloranta C . Genetic prediction of future type 2 diabetes. PLoS Med. 2007; 2(12):e345. PMC: 1274281. DOI: 10.1371/journal.pmed.0020345. View